MEMBRANOUS NEPHROPATHY - PLA2R INDUCED
Clinical trials for MEMBRANOUS NEPHROPATHY - PLA2R INDUCED explained in plain language.
Never miss a new study
Get alerted when new MEMBRANOUS NEPHROPATHY - PLA2R INDUCED trials appear
Sign up with your email to follow new studies for MEMBRANOUS NEPHROPATHY - PLA2R INDUCED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at autoimmune kidney diseases
Disease control Recruiting nowThis early-stage trial tests a new therapy called FKC289, which uses a patient's own immune cells engineered to target two proteins (BCMA and CD19) on cells that drive autoimmune attacks. The goal is to see if it is safe and can help control kidney diseases like lupus nephritis a…
Matched conditions: MEMBRANOUS NEPHROPATHY - PLA2R INDUCED
Phase: PHASE1 • Sponsor: Nanjing University School of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug aims to silence harmful antibodies in kidney disease
Disease control Recruiting nowThis study tests a drug called obinutuzumab in 20 adults with a high-risk form of membranous nephropathy, a kidney disease caused by antibodies attacking the kidneys. The goal is to see how quickly the drug lowers those harmful antibodies and whether it leads to remission. Partic…
Matched conditions: MEMBRANOUS NEPHROPATHY - PLA2R INDUCED
Phase: PHASE2, PHASE3 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC